Europe Penicillin Drug Market Size, Share & Industry Trends Analysis Report By Source (Semisynthetic Penicillin and Natural Penicillin), By Spectrum of Activity, By Distribution Channel, By Route of Administration, By Country and Growth Forecast, 2023 - 2030
The Europe Penicillin Drug Market would witness market growth of 3.2% CAGR during the forecast period (2023-2030).
Healthcare professionals are more likely to prescribe penicillin when necessary due to a better understanding of the proper indications, dose, and duration of penicillin therapy. This will contribute to the market’s growth. Patients also play a critical role in supporting market growth by immediately seeking medical treatment for bacterial illnesses and adhering to the recommended penicillin prescription.
Antibiotic use needs to be optimized, enhanced infection control strategies and the creation of new antimicrobial agents are some of the various approaches needed to combat antimicrobial resistance. As a result, the pharmaceutical industry realizes the significance of constantly enhancing and broadening the options accessible for penicillin therapy, which is predicted to fuel the expansion of the market throughout the forecast period.
Lack of good health, failing to wash hands before eating or cooking, concealing sneezing, and inadequate sanitation and hygiene routines are the main causes of increased bacterial illness. Due to this increased incidence, there is a significantly higher need for antibiotics, leading to profitable growth prospects for the market during the forecast period.
The pharmaceutical industry in Europe has a significant role in the economy and the public's interest in health care. The pharmaceutical industry's sales climbed by 5.7 percent in 2019 to reach EUR 46.4 billion. On the other hand, a general relocation of pharmaceutical manufacturers would increase expenses for the healthcare system, negatively impacting its ability to compete. In Germany, the healthcare industry accounts for one in every six employment and has an economic impact of EUR 678.2 billion (USD 798 billion), or around 12% of Germany's GDP. The market will grow as the region's healthcare industries expand.
The Germany market dominated the Europe Penicillin Drug Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $676.9 million by 2030. The UK market is estimated to grow CAGR of 2.3% during (2023 - 2030). Additionally, The France market would showcase a CAGR of 3.9% during (2023 - 2030).
Based on Source, the market is segmented into Semisynthetic Penicillin and Natural Penicillin. Based on Spectrum of Activity, the market is segmented into Broad spectrum, Extended spectrum and Narrow spectrum. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Novartis AG, Lupin Limited, Abbott Laboratories, Cipla Limited, Takeda Pharmaceutical Company Limited, Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments covered in the Report:
By Source
- Semisynthetic Penicillin
- Natural Penicillin
- Broad spectrum
- Extended spectrum
- Narrow spectrum
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
- Parenteral
- Oral
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Novartis AG
- Lupin Limited
- Abbott Laboratories
- Cipla Limited
- Takeda Pharmaceutical Company Limited
- Alkem Laboratories Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Penicillin Drug Market, by Source
- 1.4.2 Europe Penicillin Drug Market, by Spectrum of Activity
- 1.4.3 Europe Penicillin Drug Market, by Distribution Channel
- 1.4.4 Europe Penicillin Drug Market, by Route of Administration
- 1.4.5 Europe Penicillin Drug Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- Chapter 4. Competition Analysis - Global
- 4.1 KBV Cardinal Matrix
- 4.2 Recent Industry Wide Strategic Developments
- 4.2.1 Partnerships, Collaborations and Agreements
- 4.2.2 Product Launches and Product Expansions
- 4.2.3 Acquisition and Mergers
- 4.2.4 Trials and Approvals
- 4.3 Top Winning Strategies
- 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Jun – 2023, Mar) Leading Players
- 4.4 Porter Five Forces Analysis
- Chapter 5. Europe Penicillin Drug Market by Source
- 5.1 Europe Semisynthetic Penicillin Market by Country
- 5.2 Europe Natural Penicillin Market by Country
- Chapter 6. Europe Penicillin Drug Market by Spectrum of Activity
- 6.1 Europe Broad spectrum Market by Country
- 6.2 Europe Extended spectrum Market by Country
- 6.3 Europe Narrow spectrum Market by Country
- Chapter 7. Europe Penicillin Drug Market by Distribution Channel
- 7.1 Europe Drug Stores & Retail Pharmacies Market by Country
- 7.2 Europe Hospital Pharmacies Market by Country
- 7.3 Europe Online Providers Market by Country
- Chapter 8. Europe Penicillin Drug Market by Route of Administration
- 8.1 Europe Parenteral Market by Country
- 8.2 Europe Oral Market by Country
- Chapter 9. Europe Penicillin Drug Market by Country
- 9.1 Germany Penicillin Drug Market
- 9.1.1 Germany Penicillin Drug Market by Source
- 9.1.2 Germany Penicillin Drug Market by Spectrum of Activity
- 9.1.3 Germany Penicillin Drug Market by Distribution Channel
- 9.1.4 Germany Penicillin Drug Market by Route of Administration
- 9.2 UK Penicillin Drug Market
- 9.2.1 UK Penicillin Drug Market by Source
- 9.2.2 UK Penicillin Drug Market by Spectrum of Activity
- 9.2.3 UK Penicillin Drug Market by Distribution Channel
- 9.2.4 UK Penicillin Drug Market by Route of Administration
- 9.3 France Penicillin Drug Market
- 9.3.1 France Penicillin Drug Market by Source
- 9.3.2 France Penicillin Drug Market by Spectrum of Activity
- 9.3.3 France Penicillin Drug Market by Distribution Channel
- 9.3.4 France Penicillin Drug Market by Route of Administration
- 9.4 Russia Penicillin Drug Market
- 9.4.1 Russia Penicillin Drug Market by Source
- 9.4.2 Russia Penicillin Drug Market by Spectrum of Activity
- 9.4.3 Russia Penicillin Drug Market by Distribution Channel
- 9.4.4 Russia Penicillin Drug Market by Route of Administration
- 9.5 Spain Penicillin Drug Market
- 9.5.1 Spain Penicillin Drug Market by Source
- 9.5.2 Spain Penicillin Drug Market by Spectrum of Activity
- 9.5.3 Spain Penicillin Drug Market by Distribution Channel
- 9.5.4 Spain Penicillin Drug Market by Route of Administration
- 9.6 Italy Penicillin Drug Market
- 9.6.1 Italy Penicillin Drug Market by Source
- 9.6.2 Italy Penicillin Drug Market by Spectrum of Activity
- 9.6.3 Italy Penicillin Drug Market by Distribution Channel
- 9.6.4 Italy Penicillin Drug Market by Route of Administration
- 9.7 Rest of Europe Penicillin Drug Market
- 9.7.1 Rest of Europe Penicillin Drug Market by Source
- 9.7.2 Rest of Europe Penicillin Drug Market by Spectrum of Activity
- 9.7.3 Rest of Europe Penicillin Drug Market by Distribution Channel
- 9.7.4 Rest of Europe Penicillin Drug Market by Route of Administration
- Chapter 10. Company Profiles
- 10.1 Novartis AG
- 10.1.1 Company Overview
- 10.1.2 Financial Analysis
- 10.1.3 Segmental and Regional Analysis
- 10.1.4 Research & Development Expense
- 10.1.5 Recent strategies and developments:
- 10.1.5.1 Partnerships, Collaborations, and Agreements:
- 10.1.5.2 Acquisition and Mergers:
- 10.1.6 SWOT Analysis
- 10.2 Teva Pharmaceutical Industries Ltd.
- 10.2.1 Company Overview
- 10.2.2 Financial Analysis
- 10.2.3 Regional Analysis
- 10.2.4 Research & Development Expenses
- 10.2.5 SWOT Analysis
- 10.3 Sun Pharmaceutical Industries Ltd.
- 10.3.1 Company Overview
- 10.3.2 Financial Analysis
- 10.3.3 Regional Analysis
- 10.3.4 Research & Development Expenses
- 10.3.5 Recent strategies and developments:
- 10.3.5.1 Acquisition and Mergers:
- 10.3.6 SWOT Analysis
- 10.4 GlaxoSmithKline PLC (GSK)
- 10.4.1 Company Overview
- 10.4.2 Financial Analysis
- 10.4.3 Regional Analysis
- 10.4.4 Research & Development Expense
- 10.4.5 Recent strategies and developments:
- 10.4.5.1 Partnerships, Collaborations, and Agreements:
- 10.4.6 SWOT Analysis
- 10.5 Pfizer, Inc.
- 10.5.1 Company Overview
- 10.5.2 Financial Analysis
- 10.5.3 Regional & Segmental Analysis
- 10.5.4 Research & Development Expense
- 10.5.5 Recent strategies and developments:
- 10.5.5.1 Partnerships, Collaborations, and Agreements:
- 10.5.5.2 Acquisition and Mergers:
- 10.5.5.3 Trials and Approvals:
- 10.5.6 SWOT Analysis
- 10.6 Lupin Limited
- 10.6.1 Company Overview
- 10.6.2 Financial Analysis
- 10.6.3 Recent strategies and developments:
- 10.6.3.1 Partnerships, Collaborations, and Agreements:
- 10.6.4 SWOT Analysis
- 10.7 Abbott Laboratories
- 10.7.1 Company Overview
- 10.7.2 Financial Analysis
- 10.7.3 Segmental and Regional Analysis
- 10.7.4 Research & Development Expense
- 10.7.5 SWOT Analysis
- 10.8 Cipla Limited
- 10.8.1 Company Overview
- 10.8.2 Financial Analysis
- 10.8.3 Regional Analysis
- 10.8.4 Research & Development Expense
- 10.8.5 Recent strategies and developments:
- 10.8.5.1 Partnerships, Collaborations, and Agreements:
- 10.8.5.2 Acquisition and Mergers:
- 10.8.6 SWOT Analysis
- 10.9 Alkem Laboratories Ltd.
- 10.9.1 Company Overview
- 10.9.2 Financial Analysis
- 10.9.3 Regional Analysis
- 10.9.4 Research & Development Expenses
- 10.9.5 Recent strategies and developments:
- 10.9.5.1 Product Launches and Product Expansions:
- 10.9.6 SWOT Analysis
- 10.10. Takeda Pharmaceutical Company Limited
- 10.10.1 Company Overview
- 10.10.2 Financial Analysis
- 10.10.3 Regional Analysis
- 10.10.4 Research & Development Expense
- 10.10.5 Recent strategies and developments:
- 10.10.5.1 Acquisition and Mergers:
- 10.10.6 SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook